IPC’s new WHO‑SEARN status elevates India’s role in regional drug‑safety governance.
Pharmacovigilance is essential to protect public health by detecting adverse drug reactions. WHO‑SEARN was created to strengthen regulatory capacity in the region, and designating a national body as a Centre of Excellence signals confidence in its technical expertise and promotes cross‑border collaboration.
GS‑3 (Health) – Discuss how international regulatory collaborations like WHO‑SEARN enhance drug safety and quality in South‑East Asia, and assess the impact of IPC’s new status on India’s health governance.
Overview: The Indian Pharmacopoeia Commission (IPC) was formally recognised by the South‑East Asia Regulatory Network (SEARN) as the Regional Centre of Excellence in Pharmacovigilance and as a Technical Centre in Quality. The award was announced at SEARN’s 10th Anniversary Meeting in Kathmandu on 4–5 August 2026.
IPC’s new WHO‑SEARN status elevates India’s role in regional drug‑safety governance.
Pharmacovigilance is essential to protect public health by detecting adverse drug reactions. WHO‑SEARN was created to strengthen regulatory capacity in the region, and designating a national body as a Centre of Excellence signals confidence in its technical expertise and promotes cross‑border collaboration.
GS‑3 (Health) – Discuss how international regulatory collaborations like WHO‑SEARN enhance drug safety and quality in South‑East Asia, and assess the impact of IPC’s new status on India’s health governance.
No related PYQs linked to this article yet.
International health agencies and regulatory collaboration
Health governance and regulatory capacity building
International cooperation in health and drug regulation